- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01284699
Evaluation of the Safety and Efficacy of Bilateral Subthalamic Nucleus (SNT) Radiosurgery in Idiopathic Severe Parkinson's Disease Fulfilling Inclusion Criteria for STN Deep Brain Stimulation and Presenting With a Contraindication to Intracerebral Electrode Implantation.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Subthalamic nucleus (SNT) deep brain stimulation (DBS) is the reference treatment for severe drug resistant Parkinson's disease, responsible to dopaminergic therapy, to the state of complication. The efficacy of this therapeutic approach has transformed the functional prognosis of these patients. Unfortunately, those of the patients presenting with contraindications for anaesthesia or electrode implantation are excluded of these therapeutic hope.
Gamma Knife radiosurgery is a neurosurgical procedure going to operate in the brain of the patients without opening the skull without infection or bleeding risk.
Gamma Knife radiosurgical treatment will be done in two separate times (GK1 and GK2). Treatment of the second side (GK2) will be done at least 12 months after the treatment of the first side (GK1), in the same methodology as the first treatment. The major risk of onset of acute ballism although low is planned to be managed by the standard protocol by the recruiting team involved in the trial.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Marseille, France
- Assistance Publique - Hopitaux de Marseille
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- patients presenting with contraindications for anaesthesia or electrode implantation
Exclusion Criteria:
- contraindications for a surgical treatment
- Pregnant or breast-feeding women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation of the safety and efficacy
Time Frame: 48 months
|
Feasibility of this step is mandatory on the organization of a true randomized comparative trial witch should bring a higher lever of evidence, but in the present state immature from ethical point of view.
|
48 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jean -Marie REGIS, Professor, APHM
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2009-A01227-50
- 2009/34
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
EicOsis Human Health Inc.University of California, Davis; Michael J. Fox Foundation for Parkinson's...RecruitingParkinson's Disease (PD)United States
-
University of Kansas Medical CenterNot yet recruitingParkinson's Disease (PD)United States
-
AbbVieRecruiting
-
University Hospital Schleswig-HolsteinUniversity of Kiel; University of Cologne; University Hospital, Bonn; Philipps...Not yet recruitingParkinson's Disease (PD)
-
InvicroMerck Sharp & Dohme LLCRecruitingParkinson's Disease | Parkinson's Disease (PD) | Parkinson's Disease (Disorder)United States
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
Guangzhou Henovcom Bioscience Co. Ltd.Frontage Clinical Services, Inc.Active, not recruitingParkinson's Disease (PD)United States
-
Universitätsklinikum Hamburg-EppendorfUniversity of TwenteRecruitingParkinson's Disease | Deep Brain StimulationGermany
-
Mission TherapeuticsMichael J. Fox Foundation for Parkinson's Research; Parkinson's UKRecruitingParkinson's Disease (PD) | Early Stage Parkinson's Disease | Mild to Moderate Parkinson's DiseaseUnited Kingdom
Clinical Trials on Gamma Knife radiosurgery
-
Al-Azhar UniversityCompletedHypopituitarism | Pituitary Adenomas | Gamma Knife Radiosurgery | Long TermEgypt
-
Al-Azhar UniversityCompletedGamma Knife Radiosurgery | Tectal Plate GliomasEgypt
-
Elisabeth-TweeSteden ZiekenhuisZonMw: The Netherlands Organisation for Health Research and Development; Tilburg...CompletedNeoplasm MetastasesNetherlands
-
University of California, San FranciscoTerminated
-
Assistance Publique Hopitaux De MarseilleUnknown
-
CancerCare ManitobaHealth Sciences Centre Foundation, ManitobaTerminatedNeoplasm MetastasesCanada
-
Haukeland University HospitalCompleted
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Swedish Medical CenterActive, not recruiting
-
Yale UniversityTerminatedMelanoma | Sarcoma | Renal Cell Carcinoma | Breast Cancer | Colorectal Cancer | Lung Cancer | Brain Metastases | Gastrointestinal CancersUnited States